Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
41 studies found for:    " February 18, 2009":" March 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" February 18, 2009":" March 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
Conditions: HIV/AIDS;   HIV Infections
Interventions: Drug: darunavir;   Drug: Ritonavir;   Drug: Etravirine
2 Completed Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
Conditions: HIV;   HIV Infections
Interventions: Biological: V526;   Biological: Comparator: Placebo to V526
3 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
4 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
5 Completed A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers
Conditions: HIV;   HIV Infections
Interventions: Biological: Ad35-GRIN/ENV;   Biological: Ad35-GRIN
6 Active, not recruiting Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine;   Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine;   Biological: DNA vaccine placebo;   Biological: HIV-1 recombinant adenovirus vaccine placebo
7 Completed Evaluating Post-test HIV Counseling Videos for Teens
Conditions: HIV;   HIV Infections
Intervention: Behavioral: Video
8 Completed Safety of Acidform Lubricant in HIV-Uninfected Women
Condition: HIV Infections
Interventions: Drug: Acidform Lubricant;   Drug: HEC gel
9 Completed Training Community Members to Deliver HIV Prevention Programs to Urban Youth
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Be Proud! Be Responsible!;   Behavioral: Becoming A Responsible Teen (BART);   Behavioral: Reducing the Risk
10 Completed Intensive Viral Dynamics Substudy of A5248
Conditions: HIV Infections;   Treatment Naive
Intervention:
11 Completed
Has Results
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
Condition: HIV Infection
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Ritonavir;   Drug: Atazanavir;   Drug: Raltegravir;   Drug: Darunavir
12 Completed
Has Results
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
Condition: HIV Infections
Intervention:
13 Completed Asha HIV Health Promotion Intervention in India
Condition: HIV Infections
Interventions: Behavioral: ASHA LIFE;   Behavioral: USUAL Care
14 Terminated
Has Results
Minocycline for HIV+ Cognitive Impairment in Uganda
Conditions: HIV-associated Cognitive Impairment;   HIV Infections
Interventions: Drug: minocycline;   Drug: minocycline placebo capsule
15 Recruiting A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Conditions: HIV;   HIV Infections;   Pregnancy
Interventions: Drug: Darunavir;   Drug: Ritonavir;   Drug: Etravirine;   Drug: Rilpivirine;   Drug: Darunavir/Cobicistat (FDC)
16 Completed Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: AZT+3TC+ABV (Trizivir);   Drug: Switching to LPV/r monotherapy (Kaletra)
17 Completed
Has Results
Combination Pain Therapy in HIV Neuropathy
Conditions: HIV Infections;   Peripheral Neuropathy
Interventions: Drug: Duloxetine;   Drug: Duloxetine placebo;   Drug: Methadone;   Drug: Methadone placebo
18 Completed
Has Results
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
Conditions: Herpes Zoster;   HIV Infections
Interventions: Biological: ZOSTAVAX;   Biological: Placebo
19 Active, not recruiting Strategic Timing of Antiretroviral Treatment
Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
20 Withdrawn Raltegravir Activity In Lymphoid Tissues
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Efavirenz + Tenofovir DF/Emtricitabine;   Drug: Raltegravir + Tenofovir DF/Emtricitabine;   Procedure: Colonoscopy with biopsies;   Procedure: Inguinal Lymph Node Excision

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.